Zhao Jun, Tuo Yajun, Luo Wei, He Shaojun, Chen Yifei
Department of Respiratory and Critical Care Medicine, Qinghai Provincial People's Hospital, Xining, China.
Department of Endocrinology, Qinghai Provincial People's Hospital, Xining, China.
Front Physiol. 2018 May 15;9:535. doi: 10.3389/fphys.2018.00535. eCollection 2018.
A large number of studies have reported the aberrant expression of special AT-rich sequence binding protein 1 (SATB1) in colorectal cancer (CRC). However, the role of SATB1 in CRC is still controversial. Therefore, we performed this meta-analysis to elucidate the prognostic and clinical value of SATB1 in CRC patients. We searched Web of Science, EMBASE and PubMed entirely in January 2018 to identify related articles. Pooled Hazard ratio (HR) was adopted to evaluate the prognostic value of SATB1 in CRC and odd ratio (OR) was used to assess the clinicopathological significance of SATB1 in CRC. Ten eligible studies containing 7 on prognosis and 9 on clinicopathological characteristics were finally included in the present meta-analysis. Results revealed that patients with high expression of SATB1 tended to have shorter overall survival (OS) (pooled HR: 1.64, 95% CI: 1.04-2.57). Besides, we also discovered that the expression of SATB1 was associated with histologic grade (OR = 1.88, 95% CI: 1.06-3.34), distant metastasis (OR = 1.43, 95% CI: 1.11-1.85) and lymph node metastasis (OR = 1.50, 95% CI: 1.03-2.19). Broadly speaking, our meta-analysis demonstrated that high expression level of SATB1 was related to poor prognosis in CRC patients.
大量研究报道了特殊富含AT序列结合蛋白1（SATB1）在结直肠癌（CRC）中的异常表达。然而，SATB1在CRC中的作用仍存在争议。因此，我们进行了这项荟萃分析，以阐明SATB1在CRC患者中的预后和临床价值。我们在2018年1月全面检索了科学网、EMBASE和PubMed以识别相关文章。采用合并风险比（HR）评估SATB1在CRC中的预后价值，采用比值比（OR）评估SATB1在CRC中的临床病理意义。本荟萃分析最终纳入了10项符合条件的研究，其中7项关于预后，9项关于临床病理特征。结果显示，SATB1高表达的患者总生存期（OS）往往较短（合并HR：1.64，95%CI：1.04 - 2.57）。此外，我们还发现SATB1的表达与组织学分级（OR = 1.88，95%CI：1.06 - 3.34）、远处转移（OR = 1.43，95%CI：1.11 - 1.85）和淋巴结转移（OR = 1.50，95%CI：1.03 - 2.19）相关。总体而言，我们的荟萃分析表明，SATB1高表达水平与CRC患者的不良预后相关。
